Potassium Citrate

Introduction Overview

Generic Name

potassium citrate

Brand Name

Urocit-K

Dosage Form

oral tablet

Drug Class

Urinary pH modifiers

Pharmacokinetics

Absorption:
Potassium citrate is rapidly absorbed from the gastrointestinal tract upon oral administration. The absorption occurs primarily in the small intestine, where the potassium and citrate ions dissociate for uptake. Bioavailability of potassium citrate is high, facilitating efficient correction of potassium deficits and systemic alkalinization. Administration with food may slightly delay absorption but aids in reducing gastrointestinal irritation, which is a common adverse effect. Clinical data indicate that peak plasma potassium concentrations are reached within 1 to 2 hours after oral ingestion of potassium citrate tablets, underscoring its prompt onset of action in systemic alkalinization and potassium replenishment.

Distribution:
Following absorption, potassium ions are rapidly distributed into the intracellular and extracellular fluid compartments. Citrate, once absorbed, is metabolized by the liver to bicarbonate, contributing to systemic alkalinization. Potassium distribution is tightly regulated through cellular ion channels and the sodium-potassium ATPase pump, primarily localized in muscle, liver, and erythrocyte membranes. The volume of distribution approximates total body water. Citrate itself circulates transiently before metabolism and does not accumulate significantly. The drug’s distribution pattern is crucial in its clinical utility to modify urinary pH and systemic acid-base balance.

Metabolism:
Potassium citrate undergoes limited metabolism; the potassium ion remains as an active electrolyte essential for cellular function. Citrate, however, is metabolized extensively via cellular enzymatic pathways. Upon absorption, citrate enters hepatic mitochondria, where it is converted to bicarbonate through the citric acid cycle, resulting in an alkalinizing effect which reduces urinary acidity. This metabolic transformation underlies potassium citrate’s mechanistic role in preventing kidney stone formation and treating renal tubular acidosis. The conversion also facilitates correction of metabolic acidosis in susceptible patient populations.

Elimination:
Potassium is primarily eliminated via renal excretion, with the kidneys regulating plasma potassium concentrations through glomerular filtration, tubular reabsorption, and secretion processes. The urinary excretion of potassium is variable and influenced by aldosterone activity, acid-base status, and dietary intake. Citrate, after conversion, is also excreted in the urine as bicarbonate and metabolites. Potassium citrate administration results in increased urinary citrate excretion, which binds calcium and inhibits stone formation. The elimination half-life of potassium citrate is approximately 1.5 to 2 hours, necessitating multiple daily dosing to maintain therapeutic effects. Renal function significantly affects elimination; impaired kidney function may lead to elevated potassium levels and risk of hyperkalemia.

Dosage Forms

Available Dosage Forms:
Urocit-K is primarily available as an extended-release oral tablet. The tablets should be swallowed whole and are intended to release potassium and citrate ions gradually to minimize gastrointestinal irritation. Specific tablet strengths may vary by manufacturer but commonly include formulations of 5 mEq (equivalent to approximately 594 mg potassium citrate) per tablet.

Dosages for Adults and Adolescents:
The typical dosage regimen is individualized based on serum potassium levels, urinary pH targets, and underlying clinical indications such as prevention of nephrolithiasis or treatment of renal tubular acidosis. For adults and adolescents 18 years and older, potassium citrate dosing often ranges from 1 to 3 tablets taken two to three times daily, with doses adjusted based on efficacy and tolerability. The total daily potassium dose generally does not exceed 60 mEq to limit the risk of hyperkalemia. Administration with meals or immediately after a meal is advised to reduce gastrointestinal adverse effects.

Specific Patient Populations:
In patients with renal impairment, dosage adjustments are critical due to decreased potassium excretion and increased risk of hyperkalemia. Close monitoring of serum electrolytes and renal function is mandatory. Pediatric use is not approved for Urocit-K as per available data, thus safety and efficacy in children under 18 years remain undetermined. For elderly patients, careful dose titration is advised considering the potential for impaired renal function and concomitant medications affecting potassium handling. Pregnant and lactating women should use potassium citrate only if clearly needed, and under close medical supervision.

Mechanism Of Action

Potassium citrate exerts its therapeutic effects primarily through modulation of systemic and urinary pH and alteration of urinary citrate levels. Upon oral administration, potassium citrate dissociates in the gastrointestinal tract to release potassium ions and citrate anions. Citrate is metabolized to bicarbonate in hepatic cells, which contributes to systemic alkalinization. This bicarbonate generation leads to increased urinary pH, helping to create an environment unfavorable for the formation of certain types of kidney stones, particularly uric acid and cystine stones.

At the cellular level, potassium ions replenish intracellular potassium deficits, which may arise from diuretics, metabolic acidosis, or other clinical conditions. By restoring normal potassium levels, potassium citrate helps maintain intracellular electrolyte balance, essential for proper neuromuscular function and cardiac rhythm. Citrate ions additionally bind calcium in the renal tubular fluid, forming soluble complexes that reduce calcium oxalate and calcium phosphate crystallization, a major pathophysiological mechanism of stone formation.

Biochemically, the citrate-mediated increase in urinary citrate inhibits nucleation, aggregation, and growth of calcium-containing crystals by complexing free calcium and by direct effects on crystal surface properties. This dual action—systemic alkalinization and urinary calcium complexation—underlines the drug’s efficacy in preventing nephrolithiasis associated with hypocitraturia and acidic urine.

Clinically, potassium citrate is distinguished from other alkalinizing agents like sodium bicarbonate by its concomitant potassium replenishment, which mitigates potassium losses common in patients with renal tubular acidosis or on diuretics. Research and clinical studies validate its efficacy in reducing stone recurrence rates and correcting metabolic acidosis in distal renal tubular acidosis, highlighting its utility as a renal protective agent and urinary pH modifier.

Pharmacological Actions

Alkalinizes urine by metabolic conversion of citrate to bicarbonate.
Increases urinary citrate excretion, which binds calcium and prevents stone formation.
Replenishes potassium stores to correct hypokalemia.
Modulates systemic acid-base balance, treating metabolic acidosis.
Inhibits nucleation and aggregation of calcium-based kidney stones.
Reduces urinary acidity that predisposes to uric acid and cystine stone development.
Exerts a nephroprotective role in renal tubular acidosis.
Supports neuromuscular and cardiac electrical stability through potassium supplementation.
Acts as a urinary pH modifier to prevent urinary tract stone recurrence.
Enhances solubility of urinary calcium complexes via citrate binding.

Therapeutic Or Clinical Uses

Prevention and treatment of kidney stones, particularly calcium oxalate, uric acid, and cystine stones.
Management of renal tubular acidosis by correcting systemic acid-base imbalance.
Correction of hypokalemia in patients with potassium depletion.
Alkalinization of urine to reduce the risk of uric acid stone formation.
Supportive therapy in metabolic acidosis associated with chronic kidney disease.
Prevention of recurrent nephrolithiasis in patients with hypocitraturia.
Adjunctive therapy in conditions causing excessive acid load or potassium loss.
Used in patients with chronic diarrhea and acid-base disturbances.
May be utilized to maintain urinary pH in cystinuria.

Side Or Adverse Effects

Gastrointestinal irritation including nausea, vomiting, and upset stomach.
Diarrhea and abdominal discomfort.
Risk of hyperkalemia characterized by muscle weakness, fatigue, cardiac arrhythmias.
Stomach or intestinal ulcers due to local irritation.
Allergic reactions including hives, facial swelling, and difficulty breathing.
Signs of gastrointestinal bleeding such as bloody or tarry stools.
Possible tablet-induced esophageal irritation if not swallowed properly.
Electrolyte imbalances causing neuromuscular symptoms.
Potential for renal impairment exacerbation in susceptible individuals.
Risk of hypotension and bradycardia secondary to hyperkalemia.

Precautions

Avoid use in patients with hyperkalemia or predisposition to elevated serum potassium.
Use cautiously in patients with impaired renal function to prevent potassium accumulation.
Monitor electrolytes and renal function frequently during therapy.
Administer with meals or snacks to reduce gastrointestinal side effects.
Instruct patients to swallow tablets whole to avoid esophageal irritation.
Limit salt intake and ensure adequate hydration during treatment.
Avoid concomitant use with potassium-sparing diuretics unless under strict medical supervision.
Patients with gastrointestinal disorders affecting swallowing or digestion require caution.
Not approved for pediatric use; safety and efficacy in children have not been established.
Pregnant and breastfeeding women should use only if benefit justifies potential risk.

Warnings

Risk of severe hyperkalemia, which can cause life-threatening cardiac arrhythmias.
May cause serious gastrointestinal adverse events including bleeding and ulceration.
Use with caution in patients with adrenal gland disorders or untreated diabetes.
Risk of tablet-induced esophageal irritation and potential obstruction.
Contraindicated in patients with kidney failure and active urinary tract infections.
Avoid use when intestinal obstruction or significant gastrointestinal motility disorders are present.
Monitor for signs of allergic reactions such as swelling and breathing difficulty.
Careful dosage titration is required to avoid excessive alkalinization.
Regular ECG monitoring may be warranted in patients with cardiac comorbidities.
Potassium supplements or salt substitutes should not be taken concomitantly unless prescribed.

Contraindication

Hyperkalemia or elevated serum potassium concentration.
Kidney failure or severe renal impairment.
Active bladder or kidney infections.
Untreated or uncontrolled diabetes mellitus.
Adrenal gland disorders affecting electrolyte balance.
Gastrointestinal obstruction including intestinal blockage.
Esophageal, stomach, or intestinal conditions impairing swallowing or digestion.
Peptic ulcer disease present in the stomach.
Wasting syndromes or severe tissue injury such as extensive burns.
Dehydration or malnutrition states.
Concurrent use of potassium-sparing diuretics such as amiloride, eplerenone, spironolactone, or triamterene.

Drug Interactions

Concomitant use with potassium-sparing diuretics increases risk of hyperkalemia.
Increased serum potassium potentiation when combined with ACE inhibitors or ARBs.
Risk of digoxin toxicity enhanced by elevated potassium levels.
Bronchodilator medications may affect potassium homeostasis.
Cold or allergy medications containing sympathomimetics may influence potassium balance.
Diuretics (non-potassium-sparing) may alter potassium excretion dynamics.
Psychotropic medications including antidepressants and antipsychotics may interact adversely.
Medications for overactive bladder can have additive effects on potassium levels.
Parkinson’s disease treatments may alter electrolyte or renal function.
Drugs used for gastrointestinal motility or irritable bowel syndrome may influence potassium absorption.
Use with lithium requires monitoring for alterations in renal clearance.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may impair renal potassium excretion.
Coadministration with other potassium salts or supplements increases hyperkalemia risk.

Preparations Of The Drug

Extended-release oral tablets containing potassium citrate.
Potassium citrate formulations designed for gradual ion release to reduce gastrointestinal irritation.
Tablets produced in various strengths to allow dose titration based on clinical response and serum potassium monitoring.
Available as prescription-only medication in blister packs or bottles.
Formulations intended for administration with meals to improve tolerability.
Generic versions available with equivalent pharmacological profiles.
Storage recommendations include room temperature locations protected from moisture and heat.
Packaging includes safety closures to prevent pediatric ingestion.
No approved liquid formulations available under the Urocit-K brand.
Supplemental potassium citrate products distinct from Urocit-K are available for treatment of related conditions.